thiobenzoylacetone | 15473-64-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: thiobenzoylacetone
• 英文别名: Thiobenzoyl-aceton；Thiobenzoylaceton；4-Phenyl-4-sulfanylidenebutan-2-one
• CAS: 15473-64-0
• 化学式: C₁₀H₁₀OS
• 分子量: 178.255
• InChiKey: PRIZFTPMFAPSFD-UHFFFAOYSA-N

物化性质

• 沸点：
  280.2±42.0 °C(Predicted)
• 密度：
  1.121±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  49.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  hexakis(thioureato)technetium(III)-trichloride*4H2O 、 thiobenzoylacetone 以 甲醇 为溶剂， 以15%的产率得到tris(thiobenzoylacetonato)technetium(III)
  参考文献：
  名称：

  三（一硫代二苯甲酰甲基氨基）tech的and和mono一硫代-β二酮酸酯配合物及X射线结构的研究

  摘要：

  Tc（III）和Re（III）的六配位三（单硫代-β-二酮）（三价）是通过M（III）硫脲络合物与适当的单硫代-β-二酮配体在甲醇中的反应合成的。通过IR，UV-Vis，1 H NMR和质谱对化合物的表征表明，配体作为二齿配位。顺磁性物质的1 H NMR光谱得到很好的解析，螯合环质子显示Tc复合物的大高场频移和相应的Re类似物的低场频移。在三（单硫代二苯甲酰基甲基甲烷）tech（III）上进行的完整晶体和分子结构测定，是具有O和S螯合配体的Tc（III）化合物的首次结构表征。

  DOI：

  10.1016/s0020-1693(00)81739-9
• 作为产物：
  描述：

  二硫代苯甲酸甲酯 、 丙酮 生成 thiobenzoylacetone
  参考文献：
  名称：

  Uhlemann,E.; Thomas,P., Journal fur praktische Chemie (Leipzig 1954), 1966, vol. 34, p. 180 - 189

  摘要：

  DOI：

文献信息

• Bismuth(<scp>iii</scp>) β-thioxoketonates as antibiotics against Helicobacter pylori and as anti-leishmanial agents
  作者：Philip C. Andrews、Victoria L. Blair、Richard L. Ferrero、Peter C. Junk、Lukasz Kedzierski、Roshani M. Peiris

  DOI：10.1039/c3dt52544a

  日期：——

  Nine different β-thioxoketones of general formula R1C(O)CH2C(S)R2 (R1 = C6H5, R2 = C6H5L1; R1 = C6H5, R2 = p-CF3C6H4L2; R1 = p-MeOC6H4, R2 = C6H5L3; R1 = p-MeOC6H4, R2 = p-CF3C6H4L4; R1 = C5H4N, R2 = C6H5L5; R1 = p-IC6H4, R2 = C6H5L6; R1 = C6H5, R2 = p-IC6H4L7; R1 = C6H5, R2 = C10H7L8 and R1 = CH3, R2 = C6H5L9) and their tris-substituted bismuth(III) complexes having the general formula [BiR1C(O)CHC(S)R2}3] were synthesised and fully characterised. The solid state structure of [BiC5H4NC(O)CHC(S)C6H5}3] B5 was determined by crystallography and revealed that the three β-thioxoketonato ligands are bound to bismuth(III) centre in a bidentate fashion through O and S atoms. The bismuth(III) complexes and the corresponding thioxoketones were assessed for their activity against H. pylori. All of the bismuth(III) complexes were highly active against H. pylori having a MIC of greater than or equal to 3.125 μg mL−1, while the free acids were essentially not toxic to the bacteria. The anti-leishmanial activity of all the bismuth(III) β-thioxoketonates and the corresponding free acids were assessed against L. major promastigotes. The toxicity towards human fibroblast cells was also assessed. All of the free β-thioxoketones were selectively toxic to the L. major promastigotes displaying some potential as anti-leishmanial agents. Among these [C6H5C(O)CH2C(S)C6H5] L1 and [C5H4NC(O)CH2C(S)C6H5] L5 showed comparable activity to that of Amphotericin B, killing about 80% of the L. major promastigotes at a concentration of 25 μM (6.0 μg mL−1). The bismuth(III) β-thioxoketonate complexes were toxic to both the L. major promastigotes and fibroblast cells at high concentrations, but gave no improvement in anti-leishmanial activity over the free β-thioxoketones.

  通式为 R1C(O)CH2C(S)R2（R1 = C6H5，R2 = C6H5L1；R1 = C6H5，R2 = p-CF3C6H4L2；R1＝p-MeOC6H4，R2＝C6H5L3； R1＝p-MeOC6H4，R2＝p-CF3C6H4L4； R1＝C5H4N，R2＝C6H5L5； R1＝p-IC6H4，R2＝C6H5L6；R1＝C6H5，R2＝p-IC6H4L7；R1＝C6H5，R2＝C10H7L8 和 R1＝CH3，R2＝C6H5L9）及其通式为 [BiR1C(O)CHC(S)R2}3] 的三取代铋（III）配合物进行了合成和全面表征。通过晶体学方法确定了 [BiC5H4NC(O)CHC(S)C6H5}3] B5 的固态结构，发现三个δ-硫酮配体通过 O 原子和 S 原子以双齿方式与铋（III）中心结合。评估了铋（III）配合物和相应的硫酮酮对幽门螺杆菌的活性。所有铋（III）络合物对幽门螺杆菌都有很高的活性，其 MIC 大于或等于 3.125 δ¼g mLâ1 ，而游离酸对细菌基本上没有毒性。对所有δ-硫酮酸铋（III）和相应游离酸的抗大肠杆菌原虫活性进行了评估。此外，还评估了对人类成纤维细胞的毒性。所有游离的 β-thioxoketone 都能选择性地对 L. major 原虫产生毒性，显示出作为抗利什曼病原体制剂的一些潜力。其中[C6H5C(O)CH2C(S)C6H5] L1和[C5H4NC(O)CH2C(S)C6H5] L5显示出与两性霉素B相当的活性，在浓度为25δ¼M（6.0δ¼g mLâ1）时可杀死约80%的大鼠原虫。在高浓度下，δ-硫酮酸铋（III）络合物对大叶原虫和成纤维细胞都有毒性，但与游离的δ-硫酮相比，抗利什曼病的活性没有提高。
• Aroyl substituted dihydro-1,4-thiazines
  申请人：Ciba-Geigy Corporation

  公开号：US04622322A1

  公开（公告）日：1986-11-11

  Compounds of the formula ##STR1## wherein Ar is pyridyl or phenyl substituted by halogen, halo-C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkoxy, or carboxy-C.sub.1 -C.sub.4 -alkyl, n is zero, one or two, R.sub.1 is hydrogen, C.sub.1 -C.sub.4 -alkyl, heterocyclyl-C.sub.2 -C.sub.4 -alkyl, amino-C.sub.2 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 -alkylamino-C.sub.2 -C.sub.4 -alkyl, di-C.sub.1 -C.sub.4 -alkylamino-C.sub.2 -C.sub.4 -alkylor C.sub.1 -C.sub.4 -alkanoyl, and R.sub.2 is hydrogen, carboxy-C.sub.1 -C.sub.4 -alkyl, or C.sub.1 -C.sub.4 -alkoxy-carbonyl-C.sub.1 -C.sub.4 -alkyl are disclosed as well as their preparation, pharmaceutical compositions containing the same and the use thereof as antirheumatic agents.

  该化合物的公式为##STR1##其中Ar是取代有卤素，卤基-C.sub.1-C.sub.4-烷基，C.sub.1-C.sub.4-烷氧基或羧基-C.sub.1-C.sub.4-烷基的吡啶基或苯基，n为零，一或二，R.sub.1是氢，C.sub.1-C.sub.4-烷基，杂环基-C.sub.2-C.sub.4-烷基，氨基-C.sub.2-C.sub.4-烷基，C.sub.1-C.sub.4-烷基氨基-C.sub.2-C.sub.4-烷基，双-C.sub.1-C.sub.4-烷基氨基-C.sub.2-C.sub.4-烷基或C.sub.1-C.sub.4-酰基，R.sub.2是氢，羧基-C.sub.1-C.sub.4-烷基或C.sub.1-C.sub.4-烷氧基-羧酸-C.sub.1-C.sub.4-烷基，以及它们的制备方法、含有它们的制药组合物和作为抗风湿药物的用途。
• Monothio-β-diketonates of antimony(III)
  作者：V.K. Jain、R. Bohra、R.C. Mehrotra

  DOI：10.1016/s0020-1693(00)91030-2

  日期：1980.1
• US4622322A
  申请人：——

  公开号：US4622322A

  公开（公告）日：1986-11-11
• US5593970A
  申请人：——

  公开号：US5593970A

  公开（公告）日：1997-01-14